echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The third batch of national tenders opened in August! Hundreds of pharmaceutical companies usher in a brutal survival battle (with rules interpretation)

    The third batch of national tenders opened in August! Hundreds of pharmaceutical companies usher in a brutal survival battle (with rules interpretation)

    • Last Update: 2020-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On the evening of 29 July, the Joint Procurement Office of the State Organization for the Central Procurement and Use of Medicines issued the National Drug Centralized Procurement Document (GY-YD2020-1) (National Federation of Medicines (2020) No. 1).
    has been the industry's attention of the third batch of national documents officially announced, August 20 (Thursday) will be opened in Shanghai.
    The number of shortlisted enterprises up to 8 specifically, the third batch of national mining into the anatrophic, apixaban, azacin, metformin and other 56 varieties (non-nahetamine oral regular release dosage form repeated, said to be due to different adaptations separately quoted).
    the official draft and the previous industry out of the information collection list, cyclosporine, Ramifding 0.1g was transferred out.
    2019, China's public medical institutions terminal sales of more than 56 billion yuan, of which 23 drugs sales of more than 1 billion yuan.
    the second batch of rules, the volume of procurement rules change little.
    , including the eligibility of declared varieties (1.8 times the fuse mechanism and the 50% reduction rule), and the consistency of the network.
    the second batch of rules, when the actual number of enterprises that meet the "declaration variety qualification" exceeds 9, a maximum of 6 enterprises are shortlisted.
    is noteworthy that the number of shortlisted companies has increased to a maximum of eight.
    According to incomplete statistics, from the evaluation of the number, metformin oral regular release agent type through the consistency evaluation of the largest number of enterprises, up to 26, metformin slow release agent through the consistency evaluation of the enterprise also has 16.
    followed by The Catopley film, a total of 10 enterprises have been evaluated (details can refer to Sina Pharmaceuticals' previous article "The third batch of the latest content of national harvest outflow!"). 86 product codes began to be reported involving Qilu, Pfizer..."
    industry analysts said that the number of shortlisted enterprises to relax, can avoid some varieties of fierce competition, when the price reduction will be reduced.
    agreed in the first year of the procurement volume and the second batch is about the same.
    the actual number of selected enterprises is 1, 2, 3, 4 and above, the first year agreed procurement volume of each variety is 50%, 60%, 70%, 80% of the agreed procurement volume calculation base in the first year.
    there have been some changes.
    such as amosicillin, cephalosporine, cephalosporine, kramycin and other antibiotic varieties agreed to purchase in the first year on the basis of the above-mentioned base of 10%.
    the procurement cycle on the basis of the second batch of volume procurement rules, the actual selection of enterprises for 2, the current procurement cycle from 2 years to 1 year, the rest consistent.
    three injection varieties, Aza cytosine, Moxisa Star and Left Irasitan, are in principle 1 year in this procurement cycle and are not affected by the number of selected enterprises.
    100 pharmaceutical companies ushered in a brutal survival war in the third batch of national mining documents stressed that "the hospital in the priority use of the collection of varieties on the basis of the remaining dosing can be in accordance with the provisions of the collection management at that time, the appropriate amount of procurement of the same varieties of other drugs at appropriate prices."
    " does not mention the "mechanism to increase the retention of the balance of the health insurance fund" as passed on online.
    at the end of June, however, the industry issued a national health insurance bureau, the Ministry of Finance on the national organization of drug centralized procurement of medical insurance balance funds retained guidance (health insurance issue No. 2020 No. 26).
    The opinion has not yet formed an official document, which refers to the collection of pharmaceutical health insurance funds budget and balance calculation method: industry insiders said that if according to this means that the more products used, the higher the hospital's reported and dosed, the more compensation the hospital can get now the first year of procurement in various regions have been reported, some of the varieties of competitors or there is a more obvious pressure to reduce prices.
    for the unseeded enterprises, the living space is bound to be further squeezed.
    According to incomplete statistics, the third batch of national varieties involving more than 100 production enterprises, from an enterprise point of view, the original pharmaceutical companies involved in Pfizer the most varieties, followed by Merca East, Novarian and AstraZenecon;
    Zhejiang Securities Research Institute collated part of the evaluation of the enterprise market share list shows that Hengrui Pharma, Fosun Pharma's busta tablets, Hengrui Pharma's lava tablets, Fosun Pharma's pivastatin calcium tablets and other stock varieties market share and sales scale is relatively large.
    of the drug belt is designed to squeeze the drug price false high moisture, to achieve imitation alternative to the original research.
    once the bid is successful, the market share of varieties with a higher market share will further expand to achieve generic drug substitution.
    the original market share is not high varieties can also improve the profitability of preparations and cash flow situation.
    in the health insurance balance policy and national and local collection to supplement the situation, if the company does not fail to bid, its stock of large varieties of market space will gradually shrink.
    The third batch of state mining set up a "violation list" in the third batch of collection clearly requires that the enterprises participating in the collection before two years, in the pharmaceutical production activities without serious illegal records, and declared varieties within two years there is no provincial (including) or above drug supervision and administration department quality inspection non-conformity.
    is also worth noting that the collection set up a "violation list."
    If a reporting enterprise, a selected enterprise or a distribution enterprise provides prescription kickbacks or other commercial bribes, maliciously declares at a price below cost, disrupts market order, colludes with each other to declare, obtains a bribe from the purchaser, the joint procurement office, etc., and the drug in question has serious quality problems, etc., the relevant departments determine that the circumstances are serious and will be included in the "violation list".
    that enter the list face being disqualified from the election.
    , depending on the serious circumstances, disqualifies them from participating in local collection activities within 2 years from the time they enter the offending list.
    , if the selected varieties are suspended by the drug regulatory department production, sales, use, import, etc. , will be disqualified.
    In the event that it is not possible to supply or disqualify the selection, etc., the substitute supply enterprise will be determined from among the other selected enterprises, and the substitute enterprise shall supply at the selected price of the substitute enterprise, and the additional expenses incurred as a result of the guarantee of supply will also be borne by the enterprise that is unable to fulfil the agreement.
    On March 25 this year, before the second batch of national harvesting, the State Drug Administration issued a notice that because some key production facilities with yew alcohol (albumin binding type) for new-based injections do not meet the basic requirements of china's drug production quality management, there are problems such as sterile safeguards in the production process are not in place.
    shall suspend the import, sale and use of the drug in accordance with the law.
    , the Joint Procurement Office decided to disqualify the new base white purple selection, by stone medicine, Hengrui to replace the new base supply area.
    this can be said to be the "front car", reminding mining enterprises more need to ensure the quality and safety of the selected varieties.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.